Search alternatives:
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
w decrease » we decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
a large » _ large (Expand Search)
large decrease » larger decrease (Expand Search), marked decrease (Expand Search), large increases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
w decrease » we decrease (Expand Search), a decrease (Expand Search), _ decreased (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
a large » _ large (Expand Search)
-
1
Expression of lipid biosynthetic genes is decreased with polyamine depletion.
Published 2024Subjects: -
2
-
3
Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.
Published 2025“…<p>Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.…”
-
4
-
5
-
6
The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood.
Published 2025“…<p>The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood.…”
-
7
-
8
Decreased virulence observed during <i>in planta</i> infection with <i>ΔFgknr4</i>.
Published 2025“…In wheat inoculated with <i>ΔFgknr4</i> compared to WT, decreased host colonisation is observed, evidenced by (i) reduced fungal hyphae proliferation, particularly in the thicker adaxial cell layer, (ii) collapsed air spaces in wheat cells, and (iii) increased polymer deposition at the wheat cell walls (black arrows), indicating an enhanced defence response. …”
-
9
-
10
-
11
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
12
-
13
-
14
-
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
18
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
19
-
20